{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:06:26Z","timestamp":1773885986116,"version":"3.50.1"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jcrsjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.jcrs.2016.04.031","type":"journal-article","created":{"date-parts":[[2016,8,13]],"date-time":"2016-08-13T17:15:18Z","timestamp":1471108518000},"page":"1119-1125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Bromfenac ophthalmic solution 0.09% as an adjunctive therapy to topical steroids after cataract surgery in pseudoexfoliation syndrome"],"prefix":"10.1097","volume":"42","author":[{"given":"Marco","family":"Coassin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Iovieno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Soldani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Cavuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Cimino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debora","family":"Formisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210210","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jcrs.2009.03.011","article-title":"Pseudoexfoliation and the cataract surgeon: preoperative, intraoperative, and postoperative issues related to intraocular pressure, cataract, and intraocular lenses.","volume":"35","author":"Shingleton","year":"2009","journal-title":"J Cataract Refract Surg"},{"key":"R2-4-20210210","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0161-6420(98)96020-1","article-title":"Pseudoexfoliation syndrome for the comprehensive ophthalmologist; intraocular and systemic manifestations.","volume":"105","author":"Naumann","year":"1998","journal-title":"Ophthalmology"},{"key":"R8-4-20210210","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.survophthal.2009.07.005","article-title":"Nonsteroidal anti-inflammatory drugs in ophthalmology.","volume":"55","author":"Kim","year":"2010","journal-title":"Surv Ophthalmol"},{"key":"R9-4-20210210","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000320078","article-title":"Postsurgical cystoid macular edema.","volume":"47","author":"Loewenstein","year":"2010","journal-title":"Dev Ophthalmol"},{"key":"R10-4-20210210","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/S0886-3350(99)00196-0","article-title":"Cystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity.","volume":"25","author":"Ursell","year":"1999","journal-title":"J Cataract Refract Surg"},{"key":"R13-4-20210210","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.ophtha.2006.12.029","article-title":", for the Bromfenac Ophthalmic Solution 0.09 (Xibrom) Study Group. Bromfenac ophthalmic solution 0.09 (Xibrom) for postoperative ocular pain and inflammation.","volume":"114","author":"Donnenfeld","year":"2007","journal-title":"Ophthalmology"},{"key":"R15-4-20210210","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/IAE.0b013e318229b0af","article-title":"Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration; a pilot study.","volume":"32","author":"Flaxel","year":"2012","journal-title":"Retina"},{"key":"R16-4-20210210","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.ophtha.2011.04.035","article-title":", for the Bromfenac Ophthalmic Solution (Bromday) Once Daily Study Group. Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain.","volume":"118","author":"Henderson","year":"2011","journal-title":"Ophthalmology"},{"key":"R22-4-20210210","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.","volume":"140","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R23-4-20210210","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ajo.2008.06.004","article-title":"Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis.","volume":"146","author":"Kempen","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R24-4-20210210","first-page":"184","article-title":"Comparative analysis of anterior chamber flare grading between clinicians with different levels of experience and semi-automated laser flare photometry.","volume":"24","author":"Agrawal","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"R26-4-20210210","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ajo.2008.04.036","article-title":", on behalf of the Acular LS for Cystoid Macular Edema (ACME) Study Group. A randomized, masked comparison of topical ketorolac 0.4 plus steroid vs steroid alone in low-risk cataract surgery patients.","volume":"146","author":"Wittpenn","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R28-4-20210210","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ajo.2015.07.032","article-title":"Prevention of cystoid macular edema after cataract surgery in nondiabetic and diabetic patients: a systematic review and meta-analysis.","volume":"160","author":"Wielders","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R29-4-20210210","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/j.ophtha.2015.08.024","article-title":"Comparative effectiveness of three prophylactic strategies to prevent clinical macular edema after phacoemulsification surgery.","volume":"122","author":"Shorstein","year":"2015","journal-title":"Ophthalmology"}],"container-title":["Journal of Cataract and Refractive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088633501630219X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088633501630219X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1016\/j.jcrs.2016.04.031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T18:26:15Z","timestamp":1623781575000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/02158034-201608000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jcrs.2016.04.031","relation":{},"ISSN":["0886-3350"],"issn-type":[{"value":"0886-3350","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bromfenac ophthalmic solution 0.09% as\u00a0an adjunctive therapy to topical steroids\u00a0after cataract surgery in pseudoexfoliation\u00a0syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Cataract & Refractive Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcrs.2016.04.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 ASCRS and ESCRS Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}